Subtype
WHO Grade 4 Glioma
CI-CAN-00007117Explore in graph →
535 active trials3 approved drugs58 evidence items
- NCIt
- C200758
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007117Explore in graph →
Clinical trials
1,854 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (302)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03914742 | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations | completed | Phase 1 / Phase 2 | 67 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04280848 | Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma(UCPVax-Glio) | completed | Phase 2 | 67 | Centre Hospitalier Universitaire de BesanconOTHER |
| 1 |
| Jan 9, 2025 |
| clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01464177 | Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme(GBM Hypo RT) | completed | Phase 2 | 40 | Andre Tsin Chih ChenOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03732352 | 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma | completed | Phase 2 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04845919 | Sonodynamic Therapy With ExAblate System in Glioblastoma Patients(Sonic ALA) | completed | Phase 2 | 5 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT01149850 | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03234595 | A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma | completed | Phase 1 / Phase 2 | 22 | Everfront Biotech Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03661723 | Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03879512 | Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG | completed | Phase 1 / Phase 2 | 24 | Wuerzburg University HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01204684 | Dendritic Cell Vaccine for Patients With Brain Tumors | completed | Phase 2 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04013672 | Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence | completed | Phase 2 | 41 | David PeereboomOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06562621 | Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 38 | Beijing Neurosurgical InstituteOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT04492163 | Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM | completed | Phase 2 | 25 | NovoCure GmbHINDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT01817751 | Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma | completed | Phase 2 | 47 | Virginia Commonwealth UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT02014844 | Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma | completed | Phase 2 | 28 | ImmunityBio, Inc.INDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT02067156 | Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 26 | GenSpera, Inc.INDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT01591577 | Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT03139916 | Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma | completed | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT00589875 | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma(BrTK02) | completed | Phase 2 | 52 | Candel Therapeutics, Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT03466450 | Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma(GEINOGLAS) | completed | Phase 1 / Phase 2 | 75 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02052648 | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | completed | Phase 1 / Phase 2 | 160 | NewLink Genetics CorporationINDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT00704288 | Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme | completed | Phase 2 | 222 | ExelixisINDUSTRY | 1 | Feb 5, 2024 | clinicaltrials |
| NCT02206230 | Trial of Hypofractionated Radiation Therapy for Glioblastoma | completed | Phase 2 | 133 | AHS Cancer Control AlbertaOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01811498 | Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM | completed | Phase 1 / Phase 2 | 31 | Northwell HealthOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | completed | Phase 2 | 151 | Novartis PharmaceuticalsINDUSTRY | 20 | Dec 13, 2023 | clinicaltrials |
| NCT03027388 | Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma | completed | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02315534 | A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma | completed | Phase 1 / Phase 2 | 34 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Nov 15, 2023 | clinicaltrials |
| NCT03158389 | NCT Neuro Master Match - N²M² (NOA-20)(N²M²) | completed | Phase 1 / Phase 2 | 228 | University Hospital HeidelbergOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04119674 | Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 33 | Zhejiang Cancer HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT01259869 | A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression | completed | Phase 2 | 34 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 22, 2023 | clinicaltrials |
| NCT02330991 | A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse | completed | Phase 2 | 204 | Beijing Sanbo Brain HospitalOTHER | 0 | Jul 24, 2023 | clinicaltrials |
| NCT01290692 | Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma | completed | Phase 2 | 14 | TVAX BiomedicalINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT02661282 | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | completed | Phase 1 / Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02366728 | DC Migration Study for Newly-Diagnosed GBM(ELEVATE) | completed | Phase 2 | 64 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT00662506 | Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2023 | clinicaltrials |
| NCT01081223 | Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma | completed | Phase 1 / Phase 2 | 12 | TVAX BiomedicalINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT03618667 | GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification | completed | Phase 2 | 13 | Samsung Medical CenterOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT03849105 | 131I-IPA and Concurrent XRT in Recurrent GBM(IPAX-1) | completed | Phase 1 / Phase 2 | 10 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 3 | Apr 14, 2023 | clinicaltrials |
| NCT00100802 | Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 1 | Feb 15, 2023 | clinicaltrials |
| NCT04657315 | Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients(MSC11FCD-GBM) | completed | Phase 1 / Phase 2 | 10 | CHA UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT01730950 | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 182 | Radiation Therapy Oncology GroupNETWORK | 1 | Dec 29, 2022 | clinicaltrials |
| NCT04444427 | Evaluation of GLR2007 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 19 | Gan and Lee Pharmaceuticals, USAINDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT01301430 | Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.(ParvOryx01) | completed | Phase 1 / Phase 2 | 18 | Oryx GmbH & Co. KGINDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT02858895 | Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 47 | Medicenna Therapeutics, Inc.INDUSTRY | 1 | Oct 24, 2022 | clinicaltrials |
| NCT02336165 | Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma | completed | Phase 2 | 159 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 12, 2022 | clinicaltrials |
| NCT00687765 | Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 / Phase 2 | 126 | SanofiINDUSTRY | 1 | Sep 14, 2022 | clinicaltrials |
| NCT02926222 | Regorafenib in Relapsed Glioblastoma(REGOMA) | completed | Phase 2 | 119 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 9, 2022 | clinicaltrials |
| NCT03744026 | Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9(SC9-GBM-01) | completed | Phase 1 / Phase 2 | 38 | CarTheraINDUSTRY | 2 | Sep 7, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jan 14, 2025source: clinicaltrials